Monte Rosa Therapeutics, Inc. (GLUE) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Monte Rosa Therapeutics, Inc. on June 11, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Boston, MA. As of the record date (April 16, 2026), there were 84,382,573 outstanding shares of Common Stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Class II Directors
- Andrew Schiff, M.D.: Elected with 71,409,008 votes For, 741,197 Withheld, and 3,128,885 Broker Non-Votes.
- Chandra P. Leo, M.D.: Elected with 71,469,933 votes For, 680,272 Withheld, and 3,128,885 Broker Non-Votes.
- Anthony Manning, Ph.D.: Elected with 56,995,916 votes For, 15,154,289 Withheld, and 3,128,885 Broker Non-Votes. Note: Dr. Manning received a significantly higher number of withheld votes compared to the other nominees.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of Deloitte & Touche LLP for the fiscal year ending December 31, 2026.
- Votes For: 75,171,524
- Votes Against: 57,950
- Abstain: 49,616
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the reason for the high number of withheld votes (15.2 million) for director nominee Anthony Manning, Ph.D., compared to the other nominees.
- Confirm the total share count and voting power distribution as of the April 16, 2026 record date.
- Review the definitive Proxy Statement (Schedule 14A) for detailed biographies of the elected directors and the rationale for the auditor selection.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.